Table 1.
Expression profiles of marker genes with statistically significant changes during fibrosis progression
| Functional category | Description | Gene name | Expression at F1 | Group |
Expression ratio |
Serial | Type | ||
| F2/F1 | F3/F2 | F4/F3 | |||||||
| ECM (or other HSC marker) | Decorin | DCN | 217.6 | 2 | 1.21 | 1.1 | 1.1 | 1 | 1 |
| Matrix metalloproteinase 2 | MMP2 | 11.7 | 2 | 1.51 | 1.2 | 0.9 | 2 | 1 | |
| Hyaluronan-mediated motility receptor | HMMR | 1.2 | 2 | 2.61 | 0.6 | 1.1 | 3 | 1 | |
| Lysyl oxidase | LOX | 1.0 | 2 | 1.41 | 1.2 | 0.9 | 4 | 1 | |
| Lysyl oxidase-like 1 | LOXL1 | 0.8 | 2 | 1.81 | 1.4 | 1.0 | 5 | 1 | |
| Tropomyosin 1 | TPM1 | 35 | 2 | 1.81 | 1.5 | 1.1 | 6 | 1 | |
| Prion | PRNP | 19.4 | 3 | 1.21 | 0.7 | 1.0 | 7 | 1 | |
| Collagen, type I, alpha 1 | COL1A1 | 16.2 | 2 | 1.3 | 2.21 | 0.6 | 8 | 1 | |
| Collagen type III alpha 1 | COL3A1 | 143.9 | 2 | 1.3 | 1.51 | 0.8 | 9 | 1 | |
| Collagen type alpha 1 | COL4A1 | 16.8 | 2 | 1.3 | 1.91 | 0.6 | 10 | 1 | |
| Humican | LUM | 22.8 | 2 | 1.2 | 2.01 | 0.9 | 11 | 1 | |
| Sialoprotein | SPP1 | 13.2 | 2 | 1.2 | 2.21 | 1.4 | 12 | 1 | |
| Glypican 3 | GPC3 | 23.5 | 2 | 1.8 | 2.51 | 1.0 | 13 | 1 | |
| Proline 4-hydroxylase, alpha polypeptide I | P4HA1 | 34 | 1 | 1.1 | 0.42 | 1.2 | 14 | 1 | |
| Insignificant change: MGP, BGN, TAGLN, LGALS1, EDG2, EDG5, TNNT2 | |||||||||
| Inflammation (or apoptosis) | Lysozyme | LYZ | 185.3 | 2 | 2.11 | 0.8 | 1.0 | 15 | 2 |
| TGF beta | TGFB1 | 51.9 | 3 | 1.51 | 0.8 | 0.9 | 16 | 1 | |
| TGF beta 3 | TGFB3 | 3.3 | 3 | 1.41 | 0.9 | 0.9 | 17 | 3 | |
| TNF | TNF | 2.6 | 3 | 1.71 | 0.6 | 1.2 | 18 | 3 | |
| Natural killer cell proteinase 1 | GZMB | 1.7 | 3 | 1.61 | 0.5 | 1.1 | 19 | 1 | |
| IL1 beta | IL1B | 2.6 | 3 | 1.51 | 0.7 | 1.1 | 20 | 3 | |
| Hemopoietic cell kinase | HCK | 22.4 | 3 | 1.31 | 0.6 | 0.9 | 21 | 4 | |
| Interleukin 6 receptor | IL6R | 142.9 | 1 | 0.9 | 0.72 | 1.0 | 22 | 3 | |
| BCL2-related ovarian killer | BOK | 205.9 | 1 | 0.9 | 0.72 | 1.1 | 23 | 5 | |
| Caspase 2 | CASP2 | 1.3 | 1 | 1.2 | 0.72 | 0.8 | 24 | 5 | |
| Chymase 1, mast cell | CMA1 | 0.2 | 2 | 0.7 | 1.8 | 2.21 | 25 | 6 | |
| Insignificant change: LTBP1, LBP, TNFRSF1B, DEFB1, IL1RN, S100A8, BRIC3, CARD12, CASP1, CASP4, CASP8, PAWR, CD19, CD3Z, MS4A1, CD37, TRA@ | |||||||||
| Growth factor | Growth hormone receptor | GHR | 102.3 | 1 | 0.82 | 0.9 | 0.9 | 26 | 4 |
| IGF1 | IGF1 | 56.5 | 1 | 0.9 | 0.72 | 1.1 | 27 | 1 | |
| Insignificant change: PTN, FST, PRLR | |||||||||
| Insulin/ Wnt signal | Cyclin D1 | CCND1 | 190.6 | 2 | 1.71 | 1.0 | 1.0 | 28 | 5 |
| Forkhead box M1 | FOXM1 | 0.6 | 3 | 3.71 | 0.8 | 1.1 | 29 | 4 | |
| Gap junction protein, alpha 1, 43 kDa (connexin 43) | GJA1 | 4 | 3 | 2.41 | 0.5 | 1.0 | 30 | 5 | |
| V-akt murine thymoma viral oncogene homolog 1 | AKT1 | 77.6 | 1 | 0.9 | 0.92 | 1.0 | 31 | 4 | |
| V-akt murine thymoma viral oncogene homolog 2 | AKT2 | 59.6 | 1 | 0.9 | 0.72 | 0.8 | 32 | 7 | |
| Catenin (cadherin-associated protein), beta 1, 88 kDa | CTNNB1 | 159 | 1 | 1.1 | 0.72 | 1.0 | 33 | 5 | |
| Catenin, beta interacting protein 1 | CTNNBIP1 | 24 | 1 | 1.1 | 0.72 | 0.8 | 34 | 5 | |
| Glycogen synthase kinase 3 beta | GSK3B | 44.1 | 1 | 1.1 | 0.82 | 0.8 | 35 | 5 | |
| Dishevelled, dsh homolog 1 (Drosophila) | DVL1 | 12.2 | 1 | 1.1 | 0.72 | 0.9 | 36 | 7 | |
| Membrane-bound transcription factor peptidase, site 1 | MBTPS1 | 72.4 | 1 | 0.9 | 0.72 | 1.0 | 37 | 7 | |
| Membrane-bound transcription factor peptidase, site 2 | MBTPS2 | 13.2 | 1 | 0.9 | 0.72 | 1.0 | 38 | 7 | |
| Tribbles homolog 3 (Drosophila) | TRIB3 | 18.4 | 1 | 1.1 | 0.9 | 0.42 | 39 | 7 | |
| Insignificant change: GSK3A, INSIG1, INSIG2, PRKCB1, PRKCD | |||||||||
| Others signal | Regucalcin (senescence marker protein-30) | RGN | 697.8 | 1 | 0.9 | 0.8 | 0.82 | 56 | 4 |
| Insignificant change: DAB2, PMP22, S100A10, LCN2 | |||||||||
| Transcription factors | CCAAT/enhancer binding protein (C/EBP), alpha | CEBPA | 352.2 | 1 | 0.72 | 1.2 | 0.7 | 40 | 4 |
| Retinoid X receptor, alpha | RXRA | 409.6 | 1 | 0.72 | 1.0 | 0.8 | 41 | 4 | |
| Hepatocyte nuclear factor 4, alpha | HNF4A | 708.7 | 1 | 0.72 | 1.1 | 0.9 | 42 | 4 | |
| Transcription factor 1 (HNF1) | TCF1 | 26.7 | 1 | 0.82 | 0.9 | 0.8 | 43 | 4 | |
| Nuclear receptor subfamily 0, group B, member 2 | NR0B2 | 166.7 | 1 | 0.72 | 0.9 | 0.8 | 44 | 4 | |
| Peroxisome proliferative activated receptor, alpha | PPARA | 62.9 | 1 | 0.72 | 0.8 | 0.9 | 45 | 4 | |
| Inhibitor of DNA binding 1 (splice variation) | ID1 | 463.4 | 3 | 1.61 | 0.5 | 1.4 | 46 | 1 | |
| AE binding protein 1 | AEBP1 | 24.6 | 2 | 1.41 | 1.2 | 1.0 | 47 | 4 | |
| Nuclear receptor subfamily 1, group H, member 2 | NR1H2 (LXRB) | 9 | 1 | 1.2 | 0.72 | 1.0 | 48 | 7 | |
| Nuclear receptor subfamily 1, group H, member 3 | NR1H3 (LXRA) | 27.8 | 1 | 1.0 | 0.72 | 0.8 | 49 | 7 | |
| Nuclear receptor subfamily 1, group H, member 4 | NR1H4 (FXR) | 107 | 1 | 1.0 | 0.72 | 0.9 | 50 | 7 | |
| c/EBPbeta | CEBPB | 274.3 | 1 | 0.9 | 0.72 | 0.9 | 51 | 2 | |
| Upstream transcription factor 2, c-fos interacting | USF2 | 323.7 | 1 | 0.9 | 0.72 | 0.9 | 52 | 4 | |
| Estrogen-related receptor alpha | ESRRA | 79.6 | 1 | 1.2 | 0.62 | 0.8 | 53 | 7 | |
| C-met | MET | 73.5 | 1 | 1.0 | 0.72 | 1.1 | 54 | 3 | |
| Upstream transcription factor 1 | USF1 | 30.8 | 1 | 1.0 | 0.9 | 0.82 | 55 | 4 | |
| Insignificant change: ONECUT1, JUNB, NR3C1, PPARG, PPARGC1B, PPARGC1A, SREBF2, FHL2 | |||||||||
| Transporter | Solute carrier family 6, member 6 | SLC6A6 | 3.7 | 3 | 2.51 | 0.6 | 1.0 | 57 | 5 |
| Solute carrier family 7, member 1 | SLC7A1 | 0.9 | 3 | 2.31 | 0.7 | 1.3 | 58 | 5 | |
| Solute carrier family 38, member 2 Alanine-trasnporter) | SLC38A2 | 68.6 | 3 | 1.31 | 0.6 | 1.0 | 59 | 5 | |
| Solute carrier family 25 member 15 | SLC25A15 | 85.7 | 1 | 1.1 | 0.72 | 0.9 | 60 | 5 | |
| Solute carrier family 7, member 7 | SLC7A7 | 7.1 | 1 | 1.1 | 0.62 | 1.0 | 61 | 5 | |
| Solute carrier family 17 (sodium phosphate), member 1 | SLC17A1 | 23.6 | 1 | 0.9 | 0.72 | 1.0 | 62 | 4 | |
| Insignificant change: SLC38A3, ABCB1, SLC15A4 | |||||||||
| Redox | Catalase | CAT | 1977.7 | 1 | 0.82 | 0.9 | 1.0 | 63 | 4 |
| Paraoxonase 1 | PON1 | 191.1 | 1 | 0.8 | 0.72 | 0.9 | 64 | 4 | |
| Blood coagulation | Coagulation factor X | F10 | 187.5 | 1 | 0.82 | 1.0 | 0.9 | 65 | 4 |
| Angiotensinogen | AGT | 1958.4 | 1 | 0.82 | 1.0 | 1.0 | 66 | 4 | |
| Fibrinogen, A alpha polypeptide | FGA | 8337.5 | 1 | 0.62 | 1.0 | 0.9 | 67 | 4 | |
| Plasminogen | PLG | 6156.1 | 1 | 0.82 | 0.8 | 1.0 | 68 | 4 | |
| Pai I | SERPINE1 | 11.6 | 3 | 0.9 | 2.91 | 0.5 | 69 | 1 | |
| Lipid metabolism | Acyl-Coenzyme A oxidase 2, branched chain | ACOX2 | 122.2 | 1 | 0.82 | 0.9 | 0.9 | 70 | 4 |
| L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain | HADHSC | 139.8 | 1 | 0.82 | 0.9 | 0.9 | 71 | 4 | |
| Acyl-CoA synthetase long-chain family member 1 | ACSL1 | 2800.8 | 1 | 0.82 | 0.9 | 0.9 | 72 | 4 | |
| Acyl-Coenzyme A oxidase 1, palmitoyl | ACOX1 | 357.7 | 1 | 0.72 | 0.9 | 1.0 | 73 | 4 | |
| Carnitine O-octanoyltransferase | CROT | 10.3 | 1 | 0.72 | 0.8 | 1.1 | 74 | 4 | |
| 2,4-dienoyl CoA reductase 2, peroxisomal | DECR2 | 135.2 | 1 | 0.82 | 0.9 | 0.9 | 75 | 4 | |
| Acetyl-Coenzyme A acyltransferase 2 | ACAA2 | 1167.7 | 1 | 0.82 | 0.8 | 1.1 | 76 | 4 | |
| Acetyl-Coenzyme A acetyltransferase 1 | ACAT1 | 714.2 | 1 | 0.72 | 1.1 | 0.8 | 77 | 4 | |
| Acyl-CoA synthetase long-chain family member 5 | ACSL5 | 57.3 | 1 | 0.82 | 0.9 | 1.0 | 78 | 4 | |
| Dodecenoyl-Coenzyme A delta isomerase | DCI | 327.2 | 1 | 0.92 | 0.8 | 0.9 | 79 | 4 | |
| Enoyl Coenzyme A hydratase, short chain, 1, mitochondrial | ECHS1 | 324.3 | 1 | 0.72 | 1.0 | 0.9 | 80 | 4 | |
| Hydroxyacyl-Coenzyme A dehydrogenase, type II | HADH2 | 422.5 | 1 | 0.72 | 0.9 | 0.9 | 81 | 4 | |
| Hydroxyacyl-Coenzyme A dehydrogenase, beta subunit | HADHB | 398.8 | 1 | 0.82 | 0.9 | 1.1 | 82 | 4 | |
| Lipase, hepatic | LIPC | 561.5 | 1 | 0.52 | 1.5 | 0.9 | 83 | 4 | |
| Hydroxyacyl-Coenzyme A dehydrogenase, alpha subunit | HADHA | 103.2 | 1 | 0.9 | 0.92 | 1.0 | 84 | 4 | |
| Palmitoyl-protein thioesterase 1 | PPT1 | 82.1 | 1 | 1.0 | 0.82 | 0.8 | 85 | 4 | |
| Fatty acid synthase | FASN | 105.3 | 3 | 0.8 | 1.81 | 0.6 | 86 | 4 | |
| Peroxisomal D3, D2-enoyl-CoA isomerase | PECI | 292.8 | 1 | 0.8 | 0.8 | 0.82 | 87 | 4 | |
| Acyl-CoA synthetase long-chain family member 4 | ACSL4 | 5.8 | 2 | 1.1 | 1.4 | 2.31 | 88 | 4 | |
| Insignificant change: BHHADH, ACAA1, CPT1A, ACADM, ACACA, CPT2 | |||||||||
| Steroid (or drug) metabolism | Aldo-keto reductase family 1, member D1 | AKR1D1 | 248.3 | 1 | 0.62 | 0.8 | 0.6 | 89 | 4 |
| HMT1 hnRNP methyltransferase-like 2 | HRMT1L2 | 6.6 | 1 | 0.82 | 1.0 | 0.8 | 90 | 4 | |
| Hydroxysteroid (11-beta) dehydrogenase 1 | HSD11B1 | 1064.6 | 1 | 0.72 | 0.8 | 0.8 | 91 | 4 | |
| Hydroxysteroid (17-beta) dehydrogenase 4 | HSD17B4 | 66.7 | 1 | 0.82 | 0.9 | 0.9 | 92 | 4 | |
| Steroid-5-alpha-reductase, alpha polypeptide 1 | SRD5A1 | 74.3 | 1 | 0.72 | 0.8 | 0.9 | 93 | 4 | |
| UDP glycosyltransferase 2 family, polypeptide B7 | UGT2B7 | 530.3 | 1 | 0.82 | 0.8 | 0.9 | 94 | 4 | |
| Sulfotransferase family 1E, estrogen-preferring, member 1 | SULT1E1 | 52.8 | 1 | 0.52 | 0.5 | 1.4 | 95 | 7 | |
| Aldo-keto reductase family 1, member C4 | AKR1C4 | 137.1 | 1 | 0.9 | 0.62 | 1.2 | 96 | 4 | |
| Hydroxysteroid (17-beta) dehydrogenase 2 | HSD17B2 | 496.9 | 1 | 1.0 | 0.82 | 1.1 | 97 | 4 | |
| Sulfotransferase family, cytosolic, 2A, member 1 | SULT2A1 | 689 | 1 | 0.9 | 0.82 | 0.9 | 98 | 4 | |
| Hydroxysteroid (17-beta) dehydrogenase 8 | HSD17B8 | 72.2 | 1 | 0.7 | 0.72 | 1.0 | 99 | 7 | |
| Steroid sulfatase (microsomal), arylsulfatase C, isozyme S | STS | 10.9 | 1 | 1.0 | 1.0 | 0.62 | 100 | 4 | |
| Emopamil binding protein (sterol isomerase) | EBP | 197 | 1 | 1.0 | 0.7 | 0.72 | 101 | 5 | |
| Farnesyl-diphosphate farnesyltransferase 1 | FDFT1 | 252.6 | 1 | 0.7 | 0.9 | 0.72 | 102 | 5 | |
| Insignificant change: HSD17B2, HSD3B1, LCMT1, SULT2A1, HMGCR, DHCR7, CES2 | |||||||||
| Bile acid metabolism | Sterol O-acyltransferase 1 | SOAT1 | 9.1 | 1 | 1.0 | 0.82 | 0.9 | 103 | 5 |
| Alcohol dehydrogenase 1C (class I), gamma polypeptide | ADH1C | 312.7 | 1 | 0.7 | 0.62 | 1.1 | 104 | 5 | |
| Alcohol dehydrogenase, iron containing, 1 | ADHFE1 | 112.7 | 1 | 0.7 | 0.72 | 0.8 | 105 | 5 | |
| Cytochrome P450, family 7, subfamily A, polypeptide 1 | CYP7A1 | 104.1 | 1 | 0.7 | 0.62 | 2.9 | 106 | 5 | |
| Prostanoid | Arachidonate 5-lipoxygenase-activating protein | ALOX5AP | 7.9 | 2 | 1.71 | 0.7 | 1.0 | 107 | 3 |
| Leukotriene B4 receptor 2 | LTB4R2 | 2.5 | 1 | 1.1 | 0.72 | 1.0 | 108 | 3 | |
| Insignificant change: LTA4H, CYSLTR1, CYSLTR2, LTC4S, PPT1 | |||||||||
| Aromatic amino acid metabolism | Dopa decarboxylase | DDC | 51.4 | 1 | 1.0 | 0.82 | 0.8 | 109 | 4 |
| Monoamine oxidase B | MAOB | 426.6 | 1 | 0.8 | 0.82 | 1.0 | 110 | 4 | |
| Kynurenine 3-monooxygenase | KMO | 51.7 | 1 | 1.0 | 0.72 | 1.0 | 111 | 4 | |
| Kynureninase | KYNU | 63.3 | 1 | 0.9 | 0.72 | 0.8 | 112 | 4 | |
| Tyrosine aminotransferase | TAT | 658.2 | 1 | 0.9 | 0.52 | 1.3 | 113 | 4 | |
| GTP cyclohydrolase 1 | GCH1 | 49.6 | 1 | 0.9 | 0.72 | 0.9 | 114 | 4 | |
| Insignificant change: HPD | |||||||||
| Sulfur-containing amino acid metabolism | MAT2 | MAT2B | 111.7 | 1 | 1.1 | 0.72 | 1.1 | 115 | 3 |
| Cystathionase (cystathionine gamma-lyase) | CTH | 112 | 1 | 1.0 | 0.72 | 1.1 | 116 | 3 | |
| Cystathionine-beta-synthase | CBS | 350.4 | 1 | 1.1 | 0.72 | 0.9 | 117 | 3 | |
| Betaine-homocysteine methyltransferase | BHMT | 1032.1 | 1 | 1.0 | 0.72 | 1.0 | 118 | 3 | |
| Methionine adenosyltransferase I, alpha | MAT1A | 547.6 | 1 | 1.0 | 0.52 | 1.1 | 119 | 2 | |
| Cysteine dioxygenase, type I | CDO1 | 84.4 | 1 | 0.9 | 0.72 | 1 | 120 | 1 | |
| Glutamate-cysteine ligase, catalytic subunit | GCLC | 175.9 | 1 | 1.1 | 0.62 | 1.1 | 121 | 1 | |
| Glutathione S-transferase A1 | GSTA1 | 2812.3 | 1 | 1.0 | 0.72 | 1.0 | 122 | 1 | |
| Alanyl (membrane) aminopeptidase | ANPEP | 501.9 | 1 | 0.9 | 0.82 | 0.9 | 124 | 5 | |
| Bile acid Coenzyme A: amino acid N-acyltransferase | BAAT | 284.4 | 1 | 1.0 | 0.62 | 1.0 | 125 | 5 | |
| Glutathione synthetase | GSS | 70.1 | 1 | 1.1 | 0.82 | 0.8 | 126 | 5 | |
| Lactate dehydrogenase A | LDHA | 716.3 | 1 | 0.8 | 0.72 | 1.0 | 127 | 5 | |
| Mercaptopyruvate sulfurtransferase | MPST | 684.3 | 1 | 0.9 | 0.72 | 0.9 | 128 | 5 | |
| Serine dehydratase | SDS | 440.4 | 1 | 0.9 | 0.42 | 1.0 | 129 | 5 | |
| Methionine adenosyltransferase II, alpha | MAT2A | 122.9 | 1 | 1.0 | 0.9 | 0.82 | 130 | 5 | |
| Insignificant change: GGT1, GSR, MTR, DNMMT1, CSAD, GCLM, LDHB | |||||||||
| Energy source amino acid metabolism | Phosphoenolpyruvate carboxykinase 2 (mitochondrial) | PCK2 | 791.8 | 1 | 0.82 | 0.9 | 1.0 | 131 | 4 |
| Alanine-glyoxylate aminotransferase | AGXT | 3352.3 | 1 | 0.72 | 0.9 | 1.0 | 132 | 4 | |
| Alanine-glyoxylate aminotransferase 2 | AGXT2 | 122.8 | 1 | 0.62 | 0.8 | 1.0 | 133 | 4 | |
| Aldehyde dehydrogenase 2 family (mitochondrial) | ALDH2 | 2027.7 | 1 | 0.72 | 0.9 | 0.9 | 134 | 4 | |
| Aldehyde dehydrogenase 9 family, member A1 | ALDH9A1 | 160.9 | 1 | 0.82 | 0.8 | 0.9 | 135 | 4 | |
| Pyruvate kinase, liver and RBC | PKLR | 211.3 | 1 | 0.62 | 1.1 | 0.7 | 136 | 4 | |
| Aldehyde dehydrogenase 3 family, member A2 | ALDH3A2 | 237.4 | 1 | 0.9 | 0.82 | 1.1 | 137 | 4 | |
| Phosphoenolpyruvate carboxykinase 1 (soluble) | PCK1 | 3166.8 | 1 | 1.0 | 0.52 | 1.2 | 138 | 4 | |
| Dihydrolipoamide dehydrogenase | DLD | 72.3 | 1 | 0.9 | 0.82 | 0.9 | 139 | 4 | |
| Glutaminase 2 (liver, mitochondrial) | GLS2 | 133.8 | 1 | 0.8 | 0.72 | 1.0 | 140 | 4 | |
| Glutamate-ammonia ligase | GLUL | 6.2 | 1 | 1.0 | 0.62 | 1.2 | 141 | 4 | |
| Glutamic-oxaloacetic transaminase 1, soluble | GOT1 | 388.2 | 1 | 0.9 | 0.72 | 0.8 | 142 | 4 | |
| Glutamic-pyruvate transaminase | GPT | 298.8 | 1 | 0.8 | 0.62 | 1.1 | 143 | 4 | |
| Pyruvate carboxylase | PC | 27.8 | 1 | 0.7 | 0.72 | 0.9 | 144 | 4 | |
| Phosphoglucomutase 1 | PGM1 | 218.8 | 1 | 0.8 | 0.82 | 1.0 | 145 | 4 | |
| Pyruvate dehydrogenase kinase, isoenzyme 2 | PDK2 | 24 | 1 | 0.9 | 0.82 | 0.9 | 146 | 7 | |
| Pyruvate dehydrogenase kinase, isoenzyme 4 | PDK4 | 85.6 | 1 | 0.7 | 0.52 | 1.4 | 147 | 7 | |
| Fumarylacetoacetate hydrolase | FAH | 85.8 | 1 | 0.9 | 0.9 | 0.82 | 148 | 4 | |
| Malic enzyme 1, NADP (+) -dependent, cytosolic | ME1 | 4.9 | 2 | 1.0 | 1.0 | 1.31 | 149 | 4 | |
| Insignificant change: ALDOA, ASNS, GOT2, MGC33309, PDHB, PDK1 | |||||||||
| Glucose metabolism | Phosphorylase, glycogen; liver | PYGL | 37.2 | 1 | 0.82 | 1.0 | 1.0 | 150 | 4 |
| Aldolase B, fructose-bisphosphate | ALDOB | 13141.8 | 1 | 0.7 | 0.82 | 0.9 | 151 | 4 | |
| Hexokinase 3 (white cell) | HK3 | 3.3 | 1 | 1.2 | 0.62 | 0.9 | 152 | 4 | |
| Glycogen synthase 2 (liver) | GYS2 | 276.6 | 1 | 0.9 | 0.62 | 0.9 | 153 | 7 | |
| Sterol regulatory element binding transcription factor 1 | SREBF1 | 10.6 | 2 | 1.1 | 1.21 | 0.9 | 154 | 4 | |
| Glycerol-3-phosphate dehydrogenase 1 (soluble) | GPD1 | 130.8 | 1 | 0.8 | 1.0 | 0.82 | 155 | 4 | |
| Ketohexokinase (fructokinase) | KHK | 411.8 | 1 | 0.7 | 1.0 | 0.82 | 156 | 4 | |
| Glucokinase (hexokinase 4) regulator | GCKR | 204.8 | 1 | 0.7 | 1.0 | 0.82 | 157 | 4 | |
| Aldolase C, fructose-bisphosphate | ALDOC | 36.8 | 1 | 0.7 | 0.9 | 0.62 | 158 | 4 | |
| Insignificant change: GCK, PFKFB1, G6PC, HK2 | |||||||||
| Urea cycle | Carbamoyl-phosphate synthetase 1, mitochondrial | CPS1 | 1230.8 | 1 | 0.72 | 0.9 | 0.9 | 159 | 7 |
| Ornithine aminotransferase (gyrate atrophy) | OAT | 94.8 | 1 | 0.52 | 0.6 | 1.6 | 160 | 7 | |
| Insignificant change: OTC | |||||||||
Liver biopsy samples were analyzed by RT-PCR using a TaqMan® Gene Expression Assay probe, as described in the Materials and Methods. The genes were selected from DNA microarray data from a rat fibrosis model presented in a previous paper 3. Genes in the ECM category (or other HSC markers) were selected as marker genes for HSC. Genes in the inflammation category were selected as markers of inflammatory cells in liver. Other genes were selected as markers of hepatocytes. Expression profiles of marker genes that showed statistically significant changes during fibrosis by a Kruskal-Wallis test are listed. Genes that showed statistically insignificant changes in expression are listed with the gene name only in Table 1. Columns from left to right indicate functional category, gene description, gene name, expression intensity at F1 stage, group classification (expression of marker genes in group 1 decreased almost linearly along with the F stages, expression of marker genes in group 2 increased almost linearly along with the F stages, and expression of marker genes in group 3 had a peak in the middle of the F stages), expression ratio between neighbouring F stages (1an increased ratio, 2a decreased ratio), serial gene number and types of samples, which indicates the number of biopsy specimens, as shown in the Table 2. Actual alteration behavior of some characteristic genes are shown in Figure 1.